Authors' recommendations: Lapatinib (Tyverb®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with breast cancer, whose tumours overexpress HER2 (ErbB2), in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting. Lapatinib (Tyverb®) should be restricted within its licensed indication for the treatment of patients as an alternative to treatment with trastuzumab and capecitabine or trastuzumab and vinorelbine in patients in whom clinicians consider this clinically appropriate. Lapatinib (Tyverb®) is not recommended for use within NHS Wales outside of this subpopulation. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.awmsg.org/awmsgonline/app/appraisalinfo/178

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Wales, United Kingdom

Organisation Name: All Wales Medicines Strategy Group

Contact Address: All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX

Contact Name: AWTTC@wales.nhs.uk

Contact Email: AWTTC@wales.nhs.uk

Copyright: AWTTC